Intratumoral treatment of one tumor lesion with LTX-315 induces complete tumor regression and long-term specific protective immune responses in a metastatic rodent tumor model

Samankaltaisia teoksia

• LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
  Tekijä: Camilio, Ketil André, et al.
  Julkaistu: (2014)
• Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
  Tekijä: Camilio, Ketil André, et al.
  Julkaistu: (2014)
• Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
  Tekijä: Nestvold, Janne, et al.
  Julkaistu: (2017)
• Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
  Tekijä: Camilio, Ketil A., et al.
  Julkaistu: (2019)
• The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma.
  Tekijä: Liv-Marie Eike, et al.
  Julkaistu: (2016-01-01)